Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06226883 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
A Phase 2 study of Crohn's Disease and Inflammatory Bowel Diseases, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
- 20
- Study locations
NCT06226883: Recruiting Phase 2 study of Crohn's Disease and Inflammatory Bowel Diseases, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company).
NCT06226883 is a Phase 2 study of Crohn's Disease and Inflammatory Bowel Diseases that is actively recruiting participants, run by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company). The registered enrollment target is 385 participants, below the 2,391-participant average among 105 other Crohn's Disease trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06226883, a Phase 2 study of Crohn's Disease and Inflammatory Bowel Diseases, is actively recruiting participants, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Primary Outcome
The SES-CD is an endoscopic scoring system for evaluating CD activity. Endoscopic response is defined as an SES-CD decrease from baseline of ≥50%
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MORF-057
Study Locations (20)
Texas
- GI Alliance - Cedar Park - Cedar Park
- The University of Texas Health Science Center at Houston - Houston
- Texas Digestive Disease Consultants - San Marcos
- Tyler Research Institute, LLC - Tyler
North Carolina
- Cross Creek Medical Clinic - Fayetteville
- Peters Medical Research - High Point
- Wake Research Associates - Raleigh
California
- Gastro Care Institute - Lancaster
- Infinity Clinical Research - San Diego
Florida
- Clinical Research of Osceola - Kissimmee
- Bioresearch Partner-Kendale Lakes - Miami
Georgia
- Atlanta Gastroenterology Specialists, PC - Atlanta
- Atlanta Gastroenterology Associates (Part of United Digestive) - Atlanta
Other
- Medical University Hematology - Innsbruck
- Salzburg Regional Hospital - Salzburg
Colorado
- Peak Gastroenterology Associates - Colorado Springs - Colorado Springs
South Carolina
- Palmetto Gastroenterology Clinical Research - Summerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2024-07-18 |
| Est. Completion | 2030-06 |
| Phase | Phase 2 |
Sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)4 total trials
What NCT06226883 shows while recruiting
NCT06226883 is an interventional study that assigns participants to a tested intervention. The registered 385 participants enrollment target is mid-sized for trials with a published cap, below the 2,391-participant average among 105 other Crohn's Disease trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06226883 names 20 study sites across 11 states, led by Texas, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT06226883 about?
NCT06226883 is a clinical study titled "A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease". This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
What is the current status of trial NCT06226883?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2024-07-18. Estimated completion is 2030-06.
What conditions does trial NCT06226883 study?
This clinical trial studies the following conditions: Crohn's Disease, Inflammatory Bowel Diseases.
What interventions are being tested in trial NCT06226883?
The interventions under investigation include: Placebo (DRUG), MORF-057 (DRUG).
Who is sponsoring clinical trial NCT06226883?
This trial is sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06226883 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06226883's enrollment target sits among peer trials
385 30th of 105 higher than 76 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
RECRUITING · Phase 2
-
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373823 · 385 participants · NA
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
- NCT05503173 · 385 participants · NA
Telehealth for Pain and Unhealthy Drinking Among PLWH
- NCT06290063 · 385 participants · Phase 2
Cannabidiol and Older Adult Cannabis Users
- NCT06431594 · 385 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI